MeCP2 Controls Excitatory Synaptic Strength by Regulating Glutamatergic Synapse Number

Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.
Neuron (Impact Factor: 15.05). 11/2007; 56(1):58-65. DOI: 10.1016/j.neuron.2007.08.018
Source: PubMed


MeCP2 is a transcriptional repressor critical for normal neurological function. Prior studies demonstrated that either loss or doubling of MeCP2 results in postnatal neurodevelopmental disorders. To understand the impact of MeCP2 expression on neuronal function, we studied the synaptic properties of individual neurons from mice that either lack or express twice the normal levels of MeCP2. Hippocampal glutamatergic neurons that lack MeCP2 display a 46% reduction in synaptic response, whereas neurons with doubling of MeCP2 exhibit a 2-fold enhancement in synaptic response. Further analysis shows that these changes were primarily due to the number of synapses formed. These results reveal that MeCP2 is a key rate-limiting factor in regulating glutamatergic synapse formation in early postnatal development and that changes in excitatory synaptic strength may underlie global network alterations in neurological disorders due to altered MeCP2 levels.

Download full-text


Available from: Christian Rosenmund, Jan 13, 2014
  • Source
    • "like growth factor ( IGF ) also induce pro - growth signaling pathways . Like BDNF , NGF , NT - 3 , and NT - 4 , these additional trophic factors also signal through receptor tyrosine kinases to elicit downstream signaling cascades that promote growth in a variety of tissues , including neurons ( Junger and Junger , 1998 ; Ferrara et al . , 2003 ; Chao et al . , 2006 ; Reichardt , 2006 ; Laviola et al . , 2007 ) . Dysregulation in these trophic factors has been documented in ASD , and extensive work in neurodegenerative disorders has characterized their trophic and pro - survival effects in the brain , including in motor neuron atrophy ( IGF and CNTF ) , neuropathies of the peripheral nervous system ( NGF and NT - 3 ) , Alzheimer ' s disease "
    [Show abstract] [Hide abstract]
    ABSTRACT: The genetic and phenotypic heterogeneity of autism spectrum disorders (ASD) presents a substantial challenge for diagnosis, classification, research, and treatment. Investigations into the underlying molecular etiology of ASD have often yielded mixed and at times opposing findings. Defining the molecular and biochemical underpinnings of heterogeneity in ASD is crucial to our understanding of the pathophysiological development of the disorder, and has the potential to assist in diagnosis and the rational design of clinical trials. In this review, we propose that genetically diverse forms of ASD may be usefully parsed into entities resulting from converse patterns of growth regulation at the molecular level, which lead to the correlates of general synaptic and neural overgrowth or undergrowth. Abnormal brain growth during development is a characteristic feature that has been observed both in children with autism and in mouse models of autism. We review evidence from syndromic and non-syndromic ASD to suggest that entities currently classified as autism may fundamentally differ by underlying pro- or anti-growth abnormalities in key biochemical pathways, giving rise to either excessive or reduced synaptic connectivity in affected brain regions. We posit that this classification strategy has the potential not only to aid research efforts, but also to ultimately facilitate early diagnosis and direct appropriate therapeutic interventions.
    Full-text · Article · Sep 2015 · Frontiers in Neuroscience
  • Source
    • "Do neurotransmitter switches contribute to neurological disorders? Mutations in genes involved in the plasticity of synaptic strength are associated with several illnesses (Chao et al., 2007; Fromer et al., 2014; La Montanara et al., 2015). Similarly, sustained exposure to stimuli that drive transmitter switching may contribute to these conditions. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Among the many forms of brain plasticity, changes in synaptic strength and changes in synapse number are particularly prominent. However, evidence for neurotransmitter respecification or switching has been accumulating steadily, both in the developing nervous system and in the adult brain, with observations of transmitter addition, loss, or replacement of one transmitter with another. Natural stimuli can drive these changes in transmitter identity, with matching changes in postsynaptic transmitter receptors. Strikingly, they often convert the synapse from excitatory to inhibitory or vice versa, providing a basis for changes in behavior in those cases in which it has been examined. Progress has been made in identifying the factors that induce transmitter switching and in understanding the molecular mechanisms by which it is achieved. There are many intriguing questions to be addressed. Copyright © 2015 Elsevier Inc. All rights reserved.
    Full-text · Article · Jun 2015 · Neuron
    • "Altogether, these conditional animal models indicate that MeCP2 must play a role in the maintenance of brain functionality at post-natal ages. On the contrary, the investigation of the possible roles played by Mecp2 during embryonic development has been largely neglected , although it is now generally accepted that subtle but consistent impairments are present even at early post-natal ages, when typical symptoms are not yet overt (Nomura 2005; Picker et al. 2006; Chao et al. 2007; Santos et al. 2007; Fehr et al. 2011). Moreover, as already alluded, hemizygous MECP2 male patients display a severe pathological condition as early as at birth (Schüle et al. 2008; Fu et al. 2014), while MeCP2 null neurons derived from induced pluripotent stem cells (iPSCs) display defective structural and functional maturation (Marchetto et al. 2010; Okabe et al. 2010; Kim et al. 2011; Li et al. 2011; Farra et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: MeCP2 is associated with several neurological disorders; of which, Rett syndrome undoubtedly represents the most frequent. Its molecular roles, however, are still unclear, and data from animal models often describe adult, symptomatic stages, while MeCP2 functions during embryonic development remain elusive. We describe the pattern and timing of Mecp2 expression in the embryonic neocortex highlighting its low but consistent expression in virtually all cells and show the unexpected occurrence of transcriptional defects in the Mecp2 null samples at a stage largely preceding the onset of overt symptoms. Through the deregulated expression of ionic channels and glutamatergic receptors, the lack of Mecp2 during early neuronal maturation leads to the reduction in the neuronal responsiveness to stimuli. We suggest that such features concur to morphological alterations that begin affecting Mecp2 null neurons around the perinatal age and become evident later in adulthood. We indicate MeCP2 as a key modulator of the transcriptional mechanisms regulating cerebral cortex development. Neurological phenotypes of MECP2 patients could thus be the cumulative result of different adverse events that are already present at stages when no obvious signs of the pathology are evident and are worsened by later impairments affecting the central nervous system during maturation and maintenance of its functionality. © The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail:
    No preview · Article · May 2015 · Cerebral Cortex
Show more